SEC EDGARSEP 41 min read$IQV

Berkshire James G. sold (to issuer) $710K of IQV

Berkshire James G. (See Remarks) sold (to issuer) 2,713 shares of IQVIA HOLDINGS INC. (IQV) at $261.54 ($0.71M total) on 2026-09-02.

Original reporting

SEC EDGAR · Berkshire James G.

Published Sep 4, 2026, 9:00 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 4, 2026, 10:22 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$IQV

Bearish

medium confidence

Mentioned

$IQV

Relevance

5/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$IQVBearishLow

Why it matters

The disclosed sale provides fresh data for investors assessing insider sentiment and may influence short‑term trading decisions.

Market read

New insider sale information for IQVIA, useful for short‑term traders and sentiment analysis.

What to watch

Potential tax planning or diversification motives for the insider; not necessarily a bearish signal.

Relevance 5/10Novelty 7/10Timing: filing date 2026-09-04 (after market close)

Background

Form 4 filings disclose insider transactions; they are primary sources for new corporate insider activity.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$IQVBearishMedium confidence

Context

Officer James G. Berkshire sold 2,713 shares of IQVIA for $709,558 on 2026-09-02, filing a Form 4 on 2026-09-04.

Expected impact

Possible modest dip of 1-2% in the next trading session.

Evidence & confidence

The sale size ($710K) is material for an insider but not large enough to drive a major move; market may react cautiously.

Market effects

Sector

Minimal impact on the healthcare data services sector; insider activity is isolated.

Regional

U.S. equity markets only; no broader regional effect.

Global

Limited to investors tracking IQVIA.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to company outlook; price may remain stable.

Key entities

Company
IQVIA Holdings Inc.
U.S.-listed provider of health information technologies (ticker IQV).
Officer
James G. Berkshire
Company officer who reported the sale.

Read at source ← All news

SEP 19

$IQVHighAI 8/10

IQVIA Holdings (IQV) Prices $2b In Senior Notes, Is The Stock Still Undervalued?

IQVIA Holdings (IQV) priced a $2b senior notes offering due 2034. The company's share price has surged 58.8% in 90 days, with a 1-year return of 42.3%. Analysts estimate a fair value of $275.17, suggesting a modest undervaluation. However, risks include contract pricing pressure and higher leverage. The company's R&D solutions backlog and pipeline growth indicate sustained demand.

simplywall.st2 min

SEP 17

$IQVMed

Learn Why The Bull Case For IQVIA (IQV) Could Change Following AI Trial Platform Launch

IQVIA Holdings priced a $2.0b senior notes offering due 2034 to refinance debt and cover costs. The company launched IQVIA Predictive Clinical Development, an AI-driven platform aimed at accelerating clinical trials. Analysts project revenues of $20.4b and earnings of $2.0b by 2029, but debt remains a key risk. The AI platform could enhance growth and defend pricing power, though competition from in-house pharma tools is a concern.

simplywall.st3 min

SEP 10

$IQVMedAI 9/10

IQVIA Holdings Announces $2 Billion Senior Notes Offering

IQVIA Holdings plans to raise $2 billion via senior notes due 2034, with a 6.375% interest rate. Proceeds will redeem existing notes, repay credit facility debt, and cover expenses. The offering is expected to close by September 23, 2026, pending market conditions.

theglobeandmail.com1 min

SEP 10

$IQVMed

IQVIA Holdings Stock: Is IQV Outperforming the Health Care Sector?

IQVIA Holdings (IQV) has outperformed Agilent Technologies (A) in the diagnostics and research sector, with a 6.4% YTD gain and 14.7% increase over 52 weeks. Analysts give IQV a 'Strong Buy' rating, with a mean price target of $277.16, implying 7.9% upside.

finance.yahoo.com1 min

SEP 9

$IQVHighAI 8/10

IQVIA stock rises amid $2 billion senior notes offering

IQVIA Holdings Inc. (IQV) shares rose 4.3% after announcing a $2 billion senior notes offering due 2034, with a 6.375% interest rate. Proceeds will redeem existing notes, repay debt, and cover offering fees. The offering is expected to close by September 23, 2026, and is targeted at institutional buyers and non-U.S. investors. IQVIA is a global provider of clinical research and healthcare intelligence services.

investing.com1 min